{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:30:26Z","timestamp":1759026626858},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study was sponsored by Janssen Research & Development, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12185-017-2390-2","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T12:24:36Z","timestamp":1513686276000},"page":"460-467","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma"],"prefix":"10.1007","volume":"107","clinical-trial-number":[{"clinical-trial-number":"nct02497378","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shinsuke","family":"Iida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"issue":"Spec Feature","key":"2390_CR1","first-page":"70","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA. Darzalex (Daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefit. 2016;9(Spec Feature):70\u20133.","journal-title":"Am Health Drug Benefit"},{"key":"2390_CR2","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5:e349.","journal-title":"Blood Cancer J."},{"key":"2390_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"2390_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cas.12335","volume":"105","author":"K Yoshizawa","year":"2014","unstructured":"Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195\u2013201.","journal-title":"Cancer Sci"},{"key":"2390_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906\u201317.","journal-title":"N Engl J Med"},{"key":"2390_CR6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosi\u00f1ol L, Blad\u00e9 J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279\u201387.","journal-title":"J Clin Oncol."},{"key":"2390_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138.","journal-title":"Leukemia"},{"key":"2390_CR8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-014-4178-4","volume":"22","author":"N Kumar","year":"2015","unstructured":"Kumar N, Zaw AS, Reyes MR, Malhotra R, Wu PH, Makandura MC, et al. Versatility of percutaneous pedicular screw fixation in metastatic spine tumor surgery: a prospective analysis. Ann Surg Oncol. 2015;22:1604\u201311.","journal-title":"Ann Surg Oncol"},{"key":"2390_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1586\/17474086.2014.882764","volume":"7","author":"JP Laubach","year":"2014","unstructured":"Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2014;7:97\u2013111.","journal-title":"Expert Rev Hematol."},{"key":"2390_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"2390_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551\u201360.","journal-title":"Lancet."},{"key":"2390_CR12","unstructured":"Approved drugs\u2014daratumumab (DARZALEX). https:\/\/www.fda.gov\/Drugs\/informationOnDrugs\/ApprovedDrugs\/ucm530249.htm. Accessed 17 May 2017."},{"key":"2390_CR13","unstructured":"Janssen Biotech Inc. DarzalexTM (daratumumab): prescribing information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761036s004lbl.pdf. Accessed 17 May 2017."},{"key":"2390_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754\u201366.","journal-title":"N Engl J Med"},{"key":"2390_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12185-017-2281-6","volume":"106","author":"S Iida","year":"2017","unstructured":"Iida S, Suzuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, et al. Safety and efficacy of daratumumab in japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. Int J Hematol. 2017;106:541\u201351.","journal-title":"Int J Hematol"},{"key":"2390_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"2390_CR17","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"issue":"186","key":"2390_CR18","first-page":"1840","volume":"2011","author":"M de Weers","year":"1950","unstructured":"de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"2390_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","volume":"29","author":"MH Kropff","year":"2005","unstructured":"Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29:587\u201390.","journal-title":"Leuk Res"},{"key":"2390_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3324\/haematol.2014.112037","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, et al. Retrospective matched-pair analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015;100:100\u20136.","journal-title":"Haematologica"},{"issue":"suppl_6","key":"2390_CR21","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"P Moreau","year":"2013","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi133\u20137.","journal-title":"Ann Oncol."},{"key":"2390_CR22","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Moreau P, Comenzo R, Blad\u00e9 J, Benboubker L, de La Rubia J, et al. An open-label, multicenter, phase 1B study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. European Hematology Association; 2015. Abstract p. 275.","DOI":"10.1182\/blood.V124.21.176.176"},{"key":"2390_CR23","doi-asserted-by":"crossref","unstructured":"Endell J, Samuelsson C, Boxhammer R, Strauss S, Steidl S. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. J Clin Oncol. 2011;29: 2011 (suppl; abstr 8078) suppl; abstr 8078. http:\/\/meetinglibrary.asco.org\/content\/80499-102. Accessed 17 May 2017.","DOI":"10.1200\/jco.2011.29.15_suppl.8078"},{"key":"2390_CR24","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1038\/bcj.2011.42","volume":"1","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1:e41.","journal-title":"Blood Cancer J."},{"key":"2390_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207\u201319.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-017-2390-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T21:22:38Z","timestamp":1660166558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-017-2390-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2390-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]},"assertion":[{"value":"31 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}